To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action. This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm. To view information about this, please visit the FAQ. If you have any further questions, please contact us.
Standard Risk B-precursor Acute Lymphoblastic Leukemia (ALL)
Provider Data DescriptionThere are five data submissions (NCT00103285-D1, -D2, -D3, -D4, and -D5) for PMID 31825704. This dataset, NCT00103285-D1, provides the information for generating Figure 1 of consort diagram of patient enrollment. There is one row for each patient enrolled. The data cutoff is 06/30/2017.
SponsorChildren's Oncology Group
Data ProviderNational Cancer Institute
Clinical Trials.gov Information
Brief SummaryThis randomized phase III trial is studying different combination chemotherapy regimens and comparing how well they work in treating patients with newly diagnosed acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.
ConditionsAcute Lymphoblastic Leukemia Childhood B Acute Lymphoblastic Leukemia
Arms InterventionGroup 0 Induction Therapy - Experimental Group 1-SR-low ALL, Arm I (combination chemotherapy) - Active Comparator Group 1-SR-low ALL, arm II (combination chemotherapy) - Experimental Group 2-SR-avg ALL, arm I (combination chemotherapy) - Active Comparator Group 2-SR-avg ALL, arm II (combination chemotherapy) - Experimental Group 2-SR-avg ALL, arm III (combination chemotherapy) - Active Comparator Group 2-SR-avg ALL, arm IV (combination chemotherapy) - Active Comparator Group 3-SR-high ALL, combination chemotherapy - Experimental
PubMed (PMID)29284596 26590194 23678006
Collaborator(s)National Cancer Institute (NCI)
Region(s)United States Australia Canada New Zealand Switzerland
Age Range1 Year to 9 Years (Child)